MÅLOV, Denmark, Nov 21 (Reuters)- Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes
drugs come under pressure, particularly in the United States.
MÅLOV, Denmark, Nov 21 - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes
drugs come under price
pressure, particularly in the United States.